TL;DR
This study leverages a massive adverse event database to identify 135 drugs associated with venous thromboembolism (VTE), a significant and often preventable cause of hospitalization and death. Notably, 58 of these drugs lacked VTE warnings in their package inserts, highlighting a critical gap in patient safety information, particularly for anti-cancer and immunomodulating agents.
What Problem Does This Paper Address?
Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, is a major global health concern, ranking as the third leading cause of death worldwide. While VTE is known to be associated with acquired risk factors like surgery and malignancy, the role of specific medications as an acquired risk factor is often underestimated. Identifying these drug-associated VTE risks is crucial for clinical risk stratification and prevention strategies, especially for drugs with delayed or subtle thrombogenic effects. However, a comprehensive, up-to-date inventory of such risks, particularly those not clearly indicated in drug labeling, has been lacking. This paper aims to fill this gap by systematically evaluating drug-associated VTE risks using real-world pharmacovigilance data.
Methods
The researchers employed a multi-faceted approach to analyze the US Food and Drug Administration's Adverse Event Reporting System (FAERS) database from Q1 2004 to Q3 2024.
- Disproportionality Analysis: This core technique was used to identify potential associations between specific drugs and VTE. Multiple algorithms (ROR, PRR, BCPNN, MGPS) were combined to enhance the sensitivity and specificity of signal detection. Drugs were flagged if they met criteria across all four algorithms.
- Time-to-Onset (TTO) Analysis: For drugs identified with a positive VTE signal, TTO analysis was conducted to understand the temporal relationship between drug initiation and VTE occurrence. This involved calculating the duration between event and start dates and modeling the onset patterns using Weibull distribution to identify early, random, or wear-out failure modes.
- Drug Classification: The Anatomical Therapeutic Chemical (ATC) classification system was used to categorize the identified drugs, allowing for analysis of VTE risk across different drug classes.
- Package Insert Review: A critical step involved comparing the identified drug-associated VTE risks with the information present in the drugs' official package inserts to pinpoint drugs with unmentioned risks.
Datasets
The primary dataset used in this study was the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. Data from Q1 2004 to Q3 2024 were extracted, encompassing approximately 18.2 million de-duplicated adverse event reports. This massive dataset allowed for the identification of drug-associated VTE events and the analysis of associated medications. No new benchmarks were introduced; the study utilized existing, publicly available data.
Key Insights and Ideas
- Hidden Risks in Drug Labels: A significant finding is that 58 out of 135 identified drugs with positive VTE signals did not mention VTE in their package inserts. This highlights a critical need for updating drug labeling to better inform healthcare providers and patients about potential risks.
- Anti-Cancer and Immunomodulators as Major Culprits: The study strongly implicates antineoplastic and immunomodulating agents as the dominant drug category associated with VTE, accounting for nearly half of the identified high-risk drugs. This underscores the complex interplay between cancer treatment and thrombotic risk.
- Early Failure Pattern of VTE Onset: The Weibull shape parameter (β) analysis indicated an "early failure pattern" for drug-associated VTE, suggesting that the risk often manifests relatively soon after drug initiation. This has implications for monitoring patients in the initial stages of treatment.
- Specific Drugs of Concern: The study identified specific drugs with particularly high VTE risk signals, including cyproterone acetate and estradiol combination, dienogest, and drospirenone and ethinylestradiol combination.
- Demographic Trends: Females and individuals in the 45-64 age group were disproportionately affected by drug-associated VTE, providing important demographic context for risk assessment.
Key Results
- 135 Drugs Identified: The study identified 135 medications with positive signals for drug-associated VTE.
- 58 Unmentioned Risks: Of these, 58 medications did not list VTE in their package inserts.
- Dominant Categories: Antineoplastic and immunomodulating agents (47.4%) and genito-urinary system and sex hormones (25.2%) were the most frequently implicated drug categories.
- Early Onset: The median time-to-onset for drug-associated VTE was 105 days, with an early failure pattern indicated by a Weibull shape parameter of 0.649.
- Shortest Onset Times: Andexanet alfa, recombinant FVIIa, and basiliximab showed the shortest median times to VTE onset (4, 5, and 5 days, respectively).
- Demographic Distribution: Females constituted 55% of reports, and the 45-64 age group represented 34%.
- Increasing Trend: Both drug-associated VTE reports and deaths have shown an increasing trend over the study period.
Limitations and Future Work
The authors acknowledge several limitations:
- Spontaneous Reporting System Bias: FAERS relies on voluntary reporting, which can lead to inaccuracies, incompleteness, and under-reporting, especially for older drugs.
- Lack of Comprehensive Data: The database lacks crucial variables for a complete Virchow's triad assessment (hypercoagulability, blood flow stagnation, venous wall damage), limiting the ability to fully assess VTE risk.
- Inability to Calculate Incidence: As a passive surveillance system, the study could not calculate the incidence of drug-associated VTE, only signal detection.
- Correlation vs. Causation: Disproportionality analysis demonstrates correlation but cannot confirm causation.
Future work should focus on:
- Regulatory Action: Updating drug labels to reflect identified VTE risks.
- Further Research: Investigating the underlying mechanisms of VTE associated with specific drug classes, particularly anti-cancer and immunomodulating agents.
- Clinical Guidance: Providing robust, data-driven guidance for clinicians to mitigate VTE risks in pharmacotherapy.
- Validation: Further validation of findings to enhance robustness and reliability.
Summary updated